FRSHMINDS.COM: Talking Psychedelics: Jesse Hanson of Dimensions Retreats
Welcome to “Talking Psychedelics”, where Frshminds takes you on a deep dive with the driving forces shaping the psychedelics industry. Today we touch base with Jesse Hanson, PhD of Dimensions Retreats. Jesse explains the holistic approach of Dimension Retreats, how he and his colleagues spent close to a year researching ancient plant medicine traditions and the surprises that came out of that process.
PSYCHEDELICS TODAY: Modernizing Traditional Plant Medicine With Neuroscience and Luxury
In this episode, Joe interviews Christopher Dawson and Andrew Galloway: Co-Founders and CEO and COO, respectively, of Dimensions; a Canadian-based company creating retreats that blend traditional plant ceremonies with neuroscience and a luxurious, five-star environment
Most of our time this week was spent covering a sweeping, long-shot bid to legalize cannabis from Sens. Chuck Schumer, Cory Booker and Ron Wyden. The trio introduced a draft version of the bill, The Cannabis Administration and Opportunity Act (CAOA), on Wednesday.
Psyched: Nasdaq Gets Its Third Psychedelics Company , Mynd Goes Public, Delic Buys New Research Facility
The Nasdaq welcomed its third psychedelics company this week, with the acquisition of MagicMed Industries by Enveric Biosciences ENVB -1.01% in an all-stock deal. “It’s a really exclusive group listed on the Nasdaq, and that access to capital is going to be a game-changer for everybody,” MagicMed’s CEO and president Dr. Joseph Tucker told Benzinga.
New Psychedelic Company Combines Neuroscience & Ceremonial Healing
Dimensions Health Centres (“Dimensions”), a psychedelic treatment company, officially announced the company formation and subsequent closure of an initial, oversubscribed round of funding. The management team is led by CEO and Co-Founder Christopher Dawson, COO and co-founder Andrew Galloway, and Chairperson and Co-Founder David Eden.